FATE - Fate Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 51.18B
Enterprise Value 31.05B
Trailing P/E N/A
Forward P/E 1-11.52
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)145.38
Price/Book (mrq)9.26
Enterprise Value/Revenue 3129.42
Enterprise Value/EBITDA 6-13.79

Trading Information

Stock Price History

Beta (3Y Monthly) 2.32
52-Week Change 346.97%
S&P500 52-Week Change 33.55%
52 Week High 322.82
52 Week Low 311.00
50-Day Moving Average 318.53
200-Day Moving Average 318.49

Share Statistics

Avg Vol (3 month) 3787.47k
Avg Vol (10 day) 31.23M
Shares Outstanding 565.39M
Float 53.94M
% Held by Insiders 12.29%
% Held by Institutions 196.71%
Shares Short (Aug 15, 2019) 49.43M
Short Ratio (Aug 15, 2019) 413.55
Short % of Float (Aug 15, 2019) 427.51%
Short % of Shares Outstanding (Aug 15, 2019) 414.42%
Shares Short (prior month Jul 15, 2019) 48.71M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-958.25%

Management Effectiveness

Return on Assets (ttm)-34.43%
Return on Equity (ttm)-84.80%

Income Statement

Revenue (ttm)8.14M
Revenue Per Share (ttm)0.13
Quarterly Revenue Growth (yoy)174.30%
Gross Profit (ttm)-51.28M
EBITDA -76.34M
Net Income Avi to Common (ttm)-76.05M
Diluted EPS (ttm)-1.22
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)162.01M
Total Cash Per Share (mrq)2.48
Total Debt (mrq)42.59M
Total Debt/Equity (mrq)33.39
Current Ratio (mrq)5.61
Book Value Per Share (mrq)1.95

Cash Flow Statement

Operating Cash Flow (ttm)-52.38M
Levered Free Cash Flow (ttm)-34.49M